首页> 美国卫生研究院文献>Radiation Oncology (London England) >18Ffluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes
【2h】

18Ffluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes

机译:18F氟乙基胆碱-PET / CT成像用于复发和原发性前列腺癌的放射治疗计划剂量逐步增加至PET / CT阳性淋巴结

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundAt present there is no consensus on irradiation treatment volumes for intermediate to high-risk primary cancers or recurrent disease. Conventional imaging modalities, such as CT, MRI and transrectal ultrasound, are considered suboptimal for treatment decisions. Choline-PET/CT might be considered as the imaging modality in radiooncology to select and delineate clinical target volumes extending the prostate gland or prostate fossa. In conjunction with intensity modulated radiotherapy (IMRT) and imaged guided radiotherapy (IGRT), it might offer the opportunity of dose escalation to selected sites while avoiding unnecessary irradiation of healthy tissues.
机译:背景技术目前,对于中高危原发癌或复发性疾病的放射治疗量尚无共识。常规的成像方式,例如CT,MRI和经直肠超声,被认为是治疗决策的次优选择。胆碱-PET / CT可能被认为是放射肿瘤学的影像学手段,以选择和勾画扩展前列腺或前列腺窝的临床靶标量。与强度调制放疗(IMRT)和成像引导放疗(IGRT)结合使用,它可能会提供剂量逐步升级到选定部位的机会,同时避免对健康组织的不必要照射。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号